228 related articles for article (PubMed ID: 32714835)
21. Narrative review on Morbus Fabry: diagnosis and management of cardiac manifestations.
Linhart A; Paleček T
Cardiovasc Diagn Ther; 2021 Apr; 11(2):650-660. PubMed ID: 33968642
[TBL] [Abstract][Full Text] [Related]
22. AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction.
Yasuda M; Huston MW; Pagant S; Gan L; St Martin S; Sproul S; Richards D; Ballaron S; Hettini K; Ledeboer A; Falese L; Cao L; Lu Y; Holmes MC; Meyer K; Desnick RJ; Wechsler T
Mol Ther Methods Clin Dev; 2020 Sep; 18():607-619. PubMed ID: 32775495
[TBL] [Abstract][Full Text] [Related]
23. Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb₃-related analogues in Fabry disease.
Boutin M; Auray-Blais C
Anal Chem; 2014 Apr; 86(7):3476-83. PubMed ID: 24634980
[TBL] [Abstract][Full Text] [Related]
24. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
25. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
[TBL] [Abstract][Full Text] [Related]
26. Higher apoptotic state in Fabry disease peripheral blood mononuclear cells.: effect of globotriaosylceramide.
De Francesco PN; Mucci JM; Ceci R; Fossati CA; Rozenfeld PA
Mol Genet Metab; 2011 Nov; 104(3):319-24. PubMed ID: 21724436
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic challenges in two adolescent male patients with Fabry disease and high antibody titres.
Mhanni AA; Auray-Blais C; Boutin M; Johnston A; LeMoine K; Patterson J; Aerts JMFG; West ML; Rockman-Greenberg C
Mol Genet Metab Rep; 2020 Sep; 24():100618. PubMed ID: 32612933
[TBL] [Abstract][Full Text] [Related]
28. LC-MS lipidomics of renal biopsies for the diagnosis of Fabry disease.
Yazd HS; Bazargani SF; Vanbeek CA; King-Morris K; Heldermon C; Segal MS; Clapp WL; Garrett TJ
J Mass Spectrom Adv Clin Lab; 2021 Nov; 22():71-78. PubMed ID: 34918004
[TBL] [Abstract][Full Text] [Related]
29. Fabry disease: recent advances in pathology, diagnosis, treatment and monitoring.
Hoffmann B
Orphanet J Rare Dis; 2009 Oct; 4():21. PubMed ID: 19818152
[TBL] [Abstract][Full Text] [Related]
30. Monitoring enzyme replacement therapy in Fabry disease--role of urine globotriaosylceramide.
Whitfield PD; Calvin J; Hogg S; O'Driscoll E; Halsall D; Burling K; Maguire G; Wright N; Cox TM; Meikle PJ; Deegan PB
J Inherit Metab Dis; 2005; 28(1):21-33. PubMed ID: 15702403
[TBL] [Abstract][Full Text] [Related]
31. Decline of plasma brain natriuretic peptide during enzyme replacement therapy in a female patient with heterozygous Fabry's disease.
Masugata H; Senda S; Goda F; Yamagami A; Okuyama H; Kohno T; Hosomi N; Yukiiri K; Noma T; Murao K; Kohno M; Itoh S
Tohoku J Exp Med; 2009 Mar; 217(3):169-74. PubMed ID: 19282651
[TBL] [Abstract][Full Text] [Related]
32. Early therapeutic intervention in females with Fabry disease?
Hughes DA
Acta Paediatr; 2008 Apr; 97(457):41-7. PubMed ID: 18339187
[TBL] [Abstract][Full Text] [Related]
33. Long-term enzyme replacement therapy is associated with reduced proteinuria and preserved proximal tubular function in women with Fabry disease.
Prabakaran T; Birn H; Bibby BM; Regeniter A; Sørensen SS; Feldt-Rasmussen U; Nielsen R; Christensen EI
Nephrol Dial Transplant; 2014 Mar; 29(3):619-25. PubMed ID: 24215016
[TBL] [Abstract][Full Text] [Related]
34. Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.
Sasa H; Nagao M; Kino K
Mol Genet Metab; 2019 Apr; 126(4):448-459. PubMed ID: 30803893
[TBL] [Abstract][Full Text] [Related]
35. [Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature].
Riccio E; Capuano I; Visciano B; Marchetiello C; Petrillo F; Pisani A
G Ital Nefrol; 2013; 30(5):. PubMed ID: 24402625
[TBL] [Abstract][Full Text] [Related]
36. A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy.
Sheppard MN; Cane P; Florio R; Kavantzas N; Close L; Shah J; Lee P; Elliott P
Cardiovasc Pathol; 2010; 19(5):293-301. PubMed ID: 19631563
[TBL] [Abstract][Full Text] [Related]
37. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
van Breemen MJ; Rombach SM; Dekker N; Poorthuis BJ; Linthorst GE; Zwinderman AH; Breunig F; Wanner C; Aerts JM; Hollak CE
Biochim Biophys Acta; 2011 Jan; 1812(1):70-6. PubMed ID: 20851180
[TBL] [Abstract][Full Text] [Related]
38. Dose-Dependent Effect of Enzyme Replacement Therapy on Neutralizing Antidrug Antibody Titers and Clinical Outcome in Patients with Fabry Disease.
Lenders M; Neußer LP; Rudnicki M; Nordbeck P; Canaan-Kühl S; Nowak A; Cybulla M; Schmitz B; Lukas J; Wanner C; Brand SM; Brand E
J Am Soc Nephrol; 2018 Dec; 29(12):2879-2889. PubMed ID: 30385651
[TBL] [Abstract][Full Text] [Related]
39. Generation of GLA-knockout human embryonic stem cell lines to model peripheral neuropathy in Fabry disease.
Kaneski CR; Hanover JA; Schueler Hoffman UH
Mol Genet Metab Rep; 2022 Dec; 33():100914. PubMed ID: 36092250
[TBL] [Abstract][Full Text] [Related]
40. Is globotriaosylceramide a useful biomarker in Fabry disease?
Young E; Mills K; Morris P; Vellodi A; Lee P; Waldek S; Winchester B
Acta Paediatr Suppl; 2005 Mar; 94(447):51-4; discussion 37-8. PubMed ID: 15895713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
